

# John O'brien

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11142748/publications.pdf>

Version: 2024-02-01

82  
papers

14,333  
citations

50244

46  
h-index

53190

85  
g-index

89  
all docs

89  
docs citations

89  
times ranked

14232  
citing authors

#	ARTICLE	IF	CITATIONS
1	Olfactory impairment in mild cognitive impairment with Lewy bodies and Alzheimer's disease. <i>International Psychogeriatrics</i> , 2022, 34, 585-592.	0.6	10
2	Assessment of autonomic symptoms may assist with early identification of mild cognitive impairment with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	6
3	Blood pressure and heart rate responses to orthostatic challenge and Valsalva manoeuvre in mild cognitive impairment with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	4
4	A Longitudinal Study of Plasma $\tau$ 181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease. <i>Movement Disorders</i> , 2022, 37, 1495-1504.	2.2	11
5	Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTLA RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-156.	1.3	18
6	Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies. <i>Neurology</i> , 2021, 96, e2801-e2811.	1.5	25
7	Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. <i>British Journal of Psychiatry</i> , 2021, 218, 276-282.	1.7	18
8	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2021, 398, 1487-1497.	6.3	31
9	Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. <i>Stroke</i> , 2020, 51, 170-178.	1.0	115
10	Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 164.	4.5	113
11	Synaptic Loss in Primary Tauopathies Revealed by [ $^{11}\text{C}$ ]UCB-L101. <i>Movement Disorders</i> , 2020, 35, 1834-1842.	2.2	61
12	Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. <i>Alzheimer's and Dementia</i> , 2020, 16, 1571-1581.	0.4	122
13	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020, 16, 661-673.	4.9	97
14	Research with older people in a world with COVID-19: identification of current and future priorities, challenges and opportunities. <i>Age and Ageing</i> , 2020, 49, 901-906.	0.7	94
15	Competencies and training of radiographers and technologists for PET/MR imaging - a study from the UK MR-PET network. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 1.	0.6	10
16	Assessment of need and practice for assistive technology and telecare for people with dementia: The ATTLA (Assistive Technology and Telecare to maintain Independent Living At home for people with) trial. <i>Age and Ageing</i> , 2020, 49, 420-430.	1.8	19
17	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 280-292.	0.4	246
18	Predict Disease Progression With Reaction Rate Equation Modeling of Multimodal MRI and PET. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 306.	1.7	2

#	ARTICLE	IF	CITATIONS
19	Dementia: assessment, management and support: summary of updated NICE guidance. <i>BMJ: British Medical Journal</i> , 2018, 361, k2438.	2.4	77
20	Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease. <i>Cortex</i> , 2017, 92, 8-18.	1.1	32
21	The Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2017, 13, 624-633.	0.4	143
22	Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1280-1304.	1.3	39
23	Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes. <i>Ageing Research Reviews</i> , 2017, 35, 250-264.	5.0	48
24	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 85.	3.0	52
25	Support and information needs following a diagnosis of dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2016, 28, 495-501.	0.6	32
26	METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. <i>Alzheimer's and Dementia</i> , 2016, 12, 1235-1249.	0.4	82
27	Differential Atrophy of Hippocampal Subfields: A Comparative Study of Dementia with Lewy Bodies and Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 136-143.	0.6	55
28	Lessons from a pilot and feasibility randomised trial in depression (Blood pressure Rapid Intensive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.5	5
29	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , The, 2015, 14, 1171-1181.	4.9	124
30	Diagnostic Criteria for Vascular Cognitive Disorders. <i>Alzheimer Disease and Associated Disorders</i> , 2014, 28, 206-218.	0.6	529
31	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. <i>Journal of Neurology</i> , 2014, 261, 1160-1169.	1.8	16
32	fMRI resting state networks and their association with cognitive fluctuations in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2014, 4, 558-565.	1.4	93
33	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014, 3, 108.	0.8	15
34	Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change - The LADIS Study. <i>Cerebrovascular Diseases</i> , 2013, 35, 544-553.	0.8	65
35	Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 269-278.	0.8	8
36	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2013, 202, 121-128.	1.7	43

#	ARTICLE	IF	CITATIONS
37	Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. <i>BMJ Open</i> , 2012, 2, e000380.	0.8	31
38	Neuroimaging of Dementia with Lewy Bodies. <i>Neuroimaging Clinics of North America</i> , 2012, 22, 67-81.	0.5	15
39	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 366, 893-903.	13.9	626
40	2001-2011: A Decade of the LADIS (Leukoaraiosis And Disability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease?. <i>Cerebrovascular Diseases</i> , 2011, 32, 577-588.	0.8	258
41	Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2011, 378, 403-411.	6.3	444
42	Determining the minimum clinically important differences for outcomes in the DOMINO trial. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 812-817.	1.3	126
43	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. <i>BMJ: British Medical Journal</i> , 2009, 339, b2477-b2477.	2.4	348
44	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the) Tj ETQq0 010rgBT /Ovrlock 10		
45	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. <i>Trials</i> , 2009, 10, 57.	0.7	44
46	MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings. <i>Cerebrovascular Diseases</i> , 2009, 27, 336-344.	0.8	78
47	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease - The LADIS Study. <i>Cerebrovascular Diseases</i> , 2009, 27, 384-391.	0.8	167
48	Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial). <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 726-733.	0.6	73
49	Urinary Complaints in Nondisabled Elderly People with Age-Related White Matter Changes: The Leukoaraiosis And Disability (LADIS) Study. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1638-1643.	1.3	81
50	Risk of Rapid Global Functional Decline in Elderly Patients With Severe Cerebral Age-Related White Matter Changes. <i>Archives of Internal Medicine</i> , 2007, 167, 81.	4.3	187
51	Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1325-1330.	0.9	136
52	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology</i> , The, 2007, 6, 305-313.	4.9	598
53	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746.	4.9	3,755
54	Leukoaraiosis Predicts Hidden Global Functioning Impairment in Nondisabled Older People: The LADIS (Leukoaraiosis and Disability in the Elderly) Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1095-1101.	1.3	83

#	ARTICLE	IF	CITATIONS
55	Development of a Neuropsychological Battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): Experience and Baseline Data. <i>Neuroepidemiology</i> , 2006, 27, 101-116.	1.1	67
56	Age, Hypertension, and Lacunar Stroke Are the Major Determinants of the Severity of Age-Related White Matter Changes. <i>Cerebrovascular Diseases</i> , 2006, 21, 315-322.	0.8	164
57	Dementia associated with psychiatric disorders. <i>International Psychogeriatrics</i> , 2005, 17, S207-S221.	0.6	20
58	Impact of Age-Related Cerebral White Matter Changes on the Transition to Disability – The LADIS Study: Rationale, Design and Methodology. <i>Neuroepidemiology</i> , 2005, 24, 51-62.	1.1	387
59	White Matter Hyperintensities Are Associated With Impairment of Memory, Attention, and Global Cognitive Performance in Older Stroke Patients. <i>Stroke</i> , 2004, 35, 1270-1275.	1.0	118
60	Dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2004, 3, 19-28.	4.9	645
61	Systematic Review and Meta-Analysis Show that Dementia with Lewy Bodies Is a Visual-Perceptual and Attentional-Executive Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 229-237.	0.7	206
62	Behavioral Symptoms in Vascular Cognitive Impairment and Vascular Dementia. <i>International Psychogeriatrics</i> , 2003, 15, 133-138.	0.6	30
63	Vascular basis of late-onset depressive disorder. <i>British Journal of Psychiatry</i> , 2002, 180, 157-160.	1.7	158
64	Relevant clinical outcomes in probable vascular dementia and Alzheimer's disease with cerebrovascular disease. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 41-48.	0.3	7
65	Is late onset depression a prodrome to dementia?. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 997-1005.	1.3	132
66	Neuropsychological Deficits in Older Stroke Patients. <i>Annals of the New York Academy of Sciences</i> , 2002, 977, 179-182.	1.8	21
67	Structural Neuroimaging Studies in Late-Life Depression: A Review. <i>World Journal of Biological Psychiatry</i> , 2001, 2, 83-88.	1.3	47
68	Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease. <i>Archives of Neurology</i> , 2001, 58, 977.	4.9	167
69	The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 494-498.	1.3	49
70	How do memory clinics compare with traditional old age psychiatry services?. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 837-845.	1.3	47
71	Guidelines for the management of agitation in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 714-717.	1.3	101
72	Neuroimaging in dementia and depression. <i>Advances in Psychiatric Treatment</i> , 2000, 6, 109-119.	0.6	8

#	ARTICLE	IF	CITATIONS
73	The neuropsychology of dementia. The Journal of the British Menopause Society, 2000, 6, 147-153.	1.3	1
74	Neurocardiovascular Instability, Hypotensive Episodes, and MRI Lesions in Neurodegenerative Dementia. Annals of the New York Academy of Sciences, 2000, 903, 442-445.	1.8	69
75	The Association between White Matter Lesions on Magnetic Resonance Imaging and Noncognitive Symptoms. Annals of the New York Academy of Sciences, 2000, 903, 482-489.	1.8	77
76	Dementia with Lewy Bodies. Australian and New Zealand Journal of Psychiatry, 1999, 33, 800-808.	1.3	28
77	Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study. BMJ: British Medical Journal, 1998, 317, 982-984.	2.4	192
78	Naltrexone as an Adjunctive Treatment for Older Patients With Alcohol Dependence. American Journal of Geriatric Psychiatry, 1997, 5, 324-332.	0.6	127
79	Tolerability of Naltrexone in Treating Older, Alcohol-Dependent Patients. American Journal on Addictions, 1997, 6, 266-270.	1.3	9
80	Does hippocampal atrophy on MRI predict cognitive decline? A prospective follow-up study. International Journal of Geriatric Psychiatry, 1997, 12, 1182-1188.	1.3	18
81	Tolerability of Naltrexone in Treating Older, Alcohol-Dependent Patients. American Journal on Addictions, 1997, 6, 266-270.	1.3	11
82	A Magnetic Resonance Imaging Study of White Matter Lesions in Depression and Alzheimer's Disease. British Journal of Psychiatry, 1996, 168, 477-485.	1.7	215